Literature DB >> 7780245

Neonatal herpes simplex: clinical findings and outcome in relation to type of maternal infection.

G Malm1, U Berg, M Forsgren.   

Abstract

In 39 mothers of children with neonatal herpes simplex virus infection, maternal infection was serologically characterized retrospectively and was related to maternal clinical symptoms and to the clinical findings and outcome in the child. Thirteen mothers had a primary infection (six type 1, seven type 2), mostly with clinical symptoms. The mean age of onset of the disease of the infants was 7 days and a disseminated disease was most commonly found. Most of the type 1-infected children recovered completely, whereas all but one of the type 2-infected children died. Twenty mothers had a recurrent (2 type 1, 18 type 2) and 4 an intermediate infection (primary type 2, prior infection with type 1), mostly asymptomatic. Their children had a localized disease (of the skin-eye-mouth or the central nervous system) with onset at a mean age of 14 or 13 days, respectively. The frequency of neurological sequelae was high. Two mothers had no serological signs of herpes infection.

Entities:  

Mesh:

Year:  1995        PMID: 7780245     DOI: 10.1111/j.1651-2227.1995.tb13625.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  3 in total

1.  Neonatal herpes prevention: a minor public health problem in some communities.

Authors:  A Mindel; J Taylor; R L Tideman; C Seifert; G Berry; K Wagner; J Page; C Marks; B Trudinger; A Cunningham
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Prevention and management of neonatal herpes simplex virus infections.

Authors:  Upton D Allen; Joan L Robinson
Journal:  Paediatr Child Health       Date:  2014-04       Impact factor: 2.253

3.  Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum.

Authors:  G Malm; M Forsgren
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-07       Impact factor: 5.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.